NVS Novartis AG

By Olivia Bugault

Novartis AG said Saturday that pooled data from three phase III trials show that Inclisiran, an investigational treatment for hyperlipidemia in adults, has positive safety and efficacy results.

Data from the three trials, Orion-9, Orion-10 and Orion-11, "showed a durable and potent reduction in LDL-cholesterol of 51% when used in addition to other lipid-lowering therapies over 17 months of treatment," the pharmaceutical giant said.

The analysis is consistent with findings recently released in the New England Journal of Medicine, it said.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

March 30, 2020 01:43 ET (05:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.